John N. Galgiani, MD
In January, fluconazole was licensed by the Food and Drug Administration (FDA) for use in treating cryptococcosis and candidal infections in the United States. Interest in this compound among investigators has been much broader because fluconazole has shown activity in experimental animal infections that include coccidioidomycosis, histoplasmosis, blastomycosis, and aspergillosis. This azole congener is the most recent of several to be licensed for the treatment of systemic fungal infections. The first, miconazole, has not been widely used. This agent typically requires several daily parenteral doses and produces its own set of toxicities. Ketoconazole was the next azole antifungal to be
Galgiani JN. Fluconazole, a New Antifungal Agent. Ann Intern Med. ;113:177–179. doi: 10.7326/0003-4819-113-3-177
Download citation file:
Published: Ann Intern Med. 1990;113(3):177-179.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use